Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial
Sign Up to like & getrecommendations! Published in 2017 at "Mayo Clinic Proceedings"
DOI: 10.1016/j.mayocp.2016.10.009
Abstract: Objective To assess the efficacy and safety of 18 months of subcutaneous abaloparatide (ABL‐SC) or placebo (PBO) followed by 6 months of alendronate (ALN) (preplanned interim analysis). Patients and Methods ACTIVExtend, an extension of ACTIVE,… read more here.
Keywords: followed months; risk; treatment; aln ... See more keywords